Megan Fleming
Family · Salisbury, NCNPI 1134997703
Payments from drug & device makers
Across 207 payments — averaging $34.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- AstraZeneca$951
- Regeneron Healthcare Solutions, Inc.$692
- GSK$576
- Amgen$283
- Verona Pharma, Inc.$237
- plus $1K from 16 others
What the payments were for
- Consulting fees$2,10030%
- Travel & lodging$67610%
- Food & beverage$4,06458%
- Education$2203%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 14 | $3,198 |
| AstraZeneca | 32 | $951 |
| Regeneron Healthcare Solutions, Inc. | 28 | $692 |
| GSK | 46 | $576 |
| Amgen | 20 | $283 |
| Verona Pharma, Inc. | 15 | $237 |
| Actelion Pharmaceuticals US, Inc. | 5 | $188 |
| Philips North America LLC | 10 | $142 |
| Boehringer Ingelheim | 4 | $99 |
| Insmed, Inc. | 5 | $94 |
| Electromed, Inc. | 4 | $91 |
| United Therapeutics Corporation | 4 | $80 |
| Grifols USA, LLC | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Pfizer | 3 | $61 |
| Viatris Specialty LLC | 2 | $45 |
| Inspire Medical Systems, Inc. | 1 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Mylan Specialty L.p. | 2 | $36 |
| Baxter Healthcare | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,059 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 214 | $165,679 |
| OpsumitMacitentan | 13 | $165,016 |
| OfevNintedanib Esylate | 12 | $160,221 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 89 | $67,902 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 93 | $50,491 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $25,386 |
| Spiriva RespimatTiotropium Bromide | 37 | $24,608 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 35 | $23,179 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $21,249 |
| SymbicortBudesonide/Formoterol Fumarate | 86 | $20,218 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 30 | $19,099 |
| Spiriva HandihalerTiotropium Bromide | 19 | $14,405 |
| EliquisApixaban | 15 | $10,836 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 338 | $8,287 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $7,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $576 | $237,420353 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $99 | $233,394119 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $188 | $165,01613 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $951 | $107,219205 claims |
| PfizerEliquis | $61 | $10,83615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Salisbury
- Karen GarmonSalisbury$15K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.